Skip to main content
Equibles

Jefferies Financial Group Inc.

Position in NTLA — Intellia Therapeutics, Inc.

CIK 96223 NEW YORK, NY
Back to NTLA Full portfolio

Position in NTLA

as of Jun 30, 2026 · filed Aug 17, 2026
Position Value
$50,760
+$37,940 QoQ
Shares Held
3,000
+200.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#243
of 330 holders
Holding Since
Jun 2024
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Derivatives in NTLA

reported options exposure · as of Jun 30, 2026
CallValue
$2,233,440
CallShares
132,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names. NTLA ranks #65 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 PTCT
Ptc Therapeutics, Inc.
 1,357,042 $110,693,915
2 URGN
UroGen Pharma Ltd.
 2,199,652 $80,947,193
3 IMTX
Immatics N.V.
 6,506,802 $65,913,904
4 TNGX
Tango Therapeutics, Inc.
 2,010,534 $62,849,292
5 CGON
CG Oncology, Inc.
 769,947 $54,704,734
6 ARGX
Argenx SE
 45,068 $41,812,738
7 RARE
Ultragenyx Pharmaceutical Inc.
 929,626 $31,040,212
8 BMRN
Biomarin Pharmaceutical Inc
 466,258 $26,679,282

All Filings in NTLA

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,233,440 132,000
2026-06-30 $50,760 3,000
2026-03-31 $12,820 1,000
2026-03-31 $1,692,240 132,000
2024-06-30 $15,666 700
2024-06-30 $223,800 10,000